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Purpose: Hydrogel spacers are a tool to improve dosimetry and overall quality of life in men receiving 
radiotherapy for prostate cancer. This study is a pooled analysis of a prospective cohort with long-term 
quality of life (QOL) follow-up data with or without hydrogel spacers to minimize the dose to adjacent 
organs at risk. 
 
Methods and Materials: QOL was examined using the Expanded Prostate Cancer Index Composite (EPIC) 
and mean changes from baseline to EPIC domains were evaluated. A total of 215 patients from a 
randomized multi-institutional trial of radiation with or without hydrogel spacer with a QOL end-point 
were pooled with 165 non-randomized patients from a single institution with prospective QOL collection 
in patients with or without hydrogel spacer. The proportions of men with minimally important 
differences (MIDs) relative to pre-treatment baseline in the bowel domain were tested using repeated 
measure logistic models with a pre-specified threshold for clinically significant declines (>/= 5 equivalent 
to MIDx1 and >/= 10 equivalent to MIDx2). 
 
Results: A total of 380 men were evaluated (64% with spacer and 36% without) with QOL data being 
available for 199 men beyond 24 months of follow-up (median: 39.5 months, range: 31-71.4 mo). 
Treatment with spacer was associated with less decline in average long-term bowel QOL (89.4 for 
control and 94.7 for experimental) with differences at > 2 years meeting the threshold of MID difference 
between cohorts (Bowel Score Difference from baseline: control= -5.1 spacer= 0.3 Diff= -5.4 p=0.0003). 
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bowel QOL (p= 0.01). At long-term follow-up MIDx1 was 36% without spacer vs 14% with spacer 
(p=0.0006; OR=3.5, 95% CI= 1.7 – 6.9) while MIDx2 was seen in 19% vs 6% (p=0.0081; OR=3.6, 95% CI= 
1.4 – 9.1). The use of spacer was associated with less urgency with bowel movements (p=0.002) and 
fewer loose stools (p=0.009) as well as less bother with urgency (0.007) and frequency of bowel 
movements (p=0.009). 
 
Conclusions: In this pooled analysis of QOL after prostate radiotherapy with up to 5-years of follow-up, 
utilization of a rectal spacer was associated with preservation of bowel QOL.  This QOL benefit was 




Radiotherapy for prostate cancer is associated with good results in terms of both limiting toxicity and 
maximizing efficacy in men pursuing definitive therapy. Long term results in terms of cancer specific 
outcomes for surgery or radiotherapy appear similar. Patient reported outcomes (PROs) appear to be 
divergent with worse bowel quality of life (QOL) with prostate directed radiotherapy. 1 Continued gains 
in image guidance and intensity modulation have allowed for more targeted modern radiotherapeutic 
delivery utilizing both smaller margins and higher doses which may theoretically lead to better PROs. 
This approach has minimized dose to many surrounding organs at risk, except for the immediately 
adjacent plexus of nerves, vessels, and the anterior rectal wall.  
 
A rectal spacer hydrogel is available to provide a geographic barrier between the high dose immediately 
adjacent to the prostate gland and the rectum. Data has been analyzed from several series, prospective 
and retrospective, to assess for differences in toxicity and patient reported quality of life (QOL), but the 
reports to date have been with limited follow-up.2,3 It was unclear if gains in middle-term QOL with the 
rectal spacer would be maintained or only delay declines in PROs.  
 
EPIC is a standardized and validated measure of QoL for prostate cancer patients. The EPIC bowel 
domain consists of bowel function, bowel bother and a composite overall QoL evaluation. Initially within 
the literature were two series with and without hydrogel spacer in men receiving radi otherapy, however 
limited follow up was evaluable at or beyond 2 years in either cohort and therefore reduced capacity to 
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of hydrogel rectal spacer patient series with longer term follow-up of bowel related QOL: a prospective 
phase III multi-centered randomized trial and a prospective non-randomized single institution analysis of 
patients sequentially treated with or without a hydrogel spacer.  2,3 
 
Methods and Materials 
Patient Selection and Treatment Parameters 
The details of the phase III trial and non-randomized patients were previously reported.3,4 Men with 
National Comprehensive Cancer Network–determined low- or intermediate-risk prostate cancer and a 
Zubrod performance status of 0 to 1 were enrolled in a multi -institutional institutional review board–
approved single-blind phase III trial (Clinical Trials ID: NCT01538628) from 20 separate institutions. The 
exclusion criteria included prostate voluﾏe ≥8ヰ cm3, extraprostatic extension, >50% positive biopsy 
cores, previous or planned use of ADT, and/or previous treatment of prostate cancer. The patients were 
randomized 2:1 to the spacer or control group, with all men receiving fiducial markers for IGRT. The 
patients were unaware of the treatment allocation and had the fiducial markers or markers plus the 
hydrogel spacer placed without knowing to which treatment they had been randomized. Magnetic 
resonance imaging (MRI)–based planning was used, with the post-fiducial marker computed 
tomography (CT) scan fused with the magnetic resonance imaging scan. The radiation plans were 
evaluated by an independent core laboratory before treatment for compliance to the protocol 
guidelines and determination of the dosimetric endpoints. The clinical target volume was the prostate 
with or without the seminal vesicles at the physician's discretion. A planning target volume (PTV) margin 
of 5 to 10 mm was used. The radiation dose was 79.2 Gy in 1.8-Gy daily fractions, delivered 5 days 
weekly. Based upon previously published dosimetric analysis, rectal dose constraints were all less than 
rectum V50 of 50% and rectum V70 of 20% regardless of the presence of rectal spacer.
2 CT based daily 
image guidance was utilized for treatment delivery with alignment to the fiducials. 
 
In the non-randomized cohort, all 114 patients were treated from 2010 to 2011 with external beam 
radiation therapy to the prostate without pelvic lymph nodes. Treatment plans were based on a 
computed tomography scan in the supine position with a full bladder, within 3 to 5 days after hydrogel 
injection. Additionally, T2-weighted MRI scans were performed for image fusion in 27 patients after 
hydrogel injections in the initial experience and then CT scans alone were used thereafter. For the 
planning target volume, 8-mm lateral and anterior, 5-mm superior and inferior, and 4-mm posterior 
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vesicles) contours. Treatment was performed with a 5-field intensity modulated radiotherapy to a total 
dose of 76 Gy (n=96) or 78 Gy (n=18, all with hydrogel). The same objectives and constraints were used 
for inverse intensity modulated radiation therapy treatment planning for all patients: maximum rectum 
V50 = 50%, maximum rectum V70 = 20%.
3 Ultrasound-based image guidance was applied before each 
fraction. 
 
Patient reported QOL was obtained prior to radiotherapy and in follow up after radiotherapy with 
the Expanded Prostate Cancer Index Composite (EPIC) score. The rectal portion consists of an overall 
bowel QoL, referred to as EPIC Bowel QoL, score as well as a subset scores for patient reported bowel 
function and bowel bother. Practice patterns of follow-up varied by each cohort in terms of follow up. In 
the prospective randomized study, follow up occurred every 3 months for two years and then every 6 
months, while the non-randomized cohort obtained patient reported QOL surveys prior to treatment, at 
the completion of radiation, and at approximately median EPIC scores for 2, 17, and 63 months after 
treatment. 
 
Overall, a total of 380 men treated with baseline EPIC were evaluated. Specifically, 245 patients were 
treated with and 135 were treated without rectal spacer. At 12 months of follow-up, 211 patients with 
and 88 patients without rectal spacer were evaluable for PRO by EPIC (an overall 78% response rate). 
Late follow-up at or beyond 24 months was available in 128 patients with and 72 patients without (an 
o┗erall 53% response rateぶ. In the patients ┘ith an e┗aluaHle けlateげ EPIC ケuestionnaire, the ﾏedian tiﾏe 
was 40.9 months (range: 31.1-71.4 months) from treatment.   
 
Statistical Analysis 
Demographic and patient characteristics were described between treatment groups and patient cohorts 
separately.  Chi-square tests for stage and Gleason, t-tests for age and Wilcoxon rank tests for percent 
positive cores were provided.  EPIC was evaluated by overall EPIC Bowel QoL, Bowel bother, and Bowel 
Function as well as by each individual question within the bowel domain. Based on standard 
interpretation of the EPIC bowel QOL, a けsignificantげ score change of 5 points ┘as defined as a ﾏiniﾏally 
iﾏportant difference ふMIDぶ and scored as MID┝1 and a けse┗ereげ score change of 1ヰ points ┘as 
considered a MIDx2.5 Due to alterations in follow-up patterns Het┘een cohorts, けlateげ follow-up was 
defined as at least 24 months post-treatment.  The bowel domain analysis of the individual items 
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comparison adjustments were not made as these are only used to identify the areas of the bowel score 
that differ for descriptive purposes.   
 
The bowel score differences from baseline were modeled using longitudinal repeated measures with 
interest in the effect of treatment differences over time (months since treatment that the EPIC 
questionnaire was completed.)  Treatment, months since treatment, and interaction effect were 
included in the model.  Repeated measures within a patient used an autoregressive correlation 
structure. Treatment by month estimates and pairwise testing was done within the modeling 
framework. Each binary MID endpoint was presented with proportions and binomial confidence 
intervals by treatment and questionnaire months.  Analysis was performed in SAS, version 9.4 (SAS 
Institute, Cary, NC).  
 
Results 
Patient Baseline Characteristics 
All evaluable baseline treatment characteristics shared by the two patient cohorts are in Table 1 with 
evaluation of differences in the baseline characteristics based on utilization of hydrogel and between 
randomized and non-randomized patient subsets. Baseline characteristics were similar between the 
groups with or without rectal hydrogel spacer except for patients with hydrogel spacer being younger at 
the time of treatment. Comparing patients between randomized and non-randomized cohorts, there 
were associations towards older patients, lower rates of cT2 stage, more Gleason grade 7, higher 
percentage of positive cores on diagnostic biopsy, worse baseline EPIC bowel function score. However 
differences between the baseline EPIC differences were not clinically meaningful based on MID and 
overall bowel EPIC summary scores were not statistically or clinically different.  
 
Patient Reported Bowel Quality of Life 
Radiotherapy to the prostate with rectal hydrogel spacer was associated with less decline in mean long-
term overall Bowel EPIC summary score for overall bowel QOL (89.4 for control and 94.7 for 
experimental) with modelled differences at 1 year compared to baseline diverging statistically (p=0.005, 
Figure 1). Beyond this time point, differences continued to diverge while remaining statistically different.  
At 2 years, differences between the control and hydrogel rectal spacer cohorts was meeting the 
threshold a clinically meaningful difference (Bowel Score Difference from baseline: control= -5.1 spacer= 
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threshold for clinically significant decline was maintained for MIDx1 difference between the cohorts 
through 5 years of follow up (p=0.002). MIDx1 was trending towards significance at 12 months of follow 
up (p=0.0735) and no difference in MIDx2. At 15 months of follow-up, MIDx1 and MIDx2 were both 
more frequent in patients without rectal spacer (MIDx1 at 15 months p= 0.0371 and MIDx2 at 15 
months p=0.0007). The model for bowel difference was associated better PRO of bowel function 
(p=0.0282). When adjusting for multiple questionnaires being completed over time, it confirmed 
increased risk of reduced bowel QOL overtime in patients without rectal spacer compared to those with 
spacer (p<0.0001). 
 
Clinically relevant declines were noted beyond statistical differences and modeled data. At long-term 
follow-up MIDx1 was 36% without spacer vs 14% with spacer (p=0.0006, Odds Ratio=3.5,  95% 
confidence interval 1.7-6.9, Figure 2) while MIDx2 was seen in 19% vs 6% (p=0.0081, Odds Ratio=3.6, 
95% confidence interval 1.4-9.1). Differences in MIDx1 and MIDx2 between hydrogel spacer and 
controlled corroborates statical differences at later follow-up beyond one year (Figure 2). 
 
Specific aspects of bowel related quality of life were improved with rectal spacer placement relative to 
control (Table 2). Patients without hydrogel spacer were more likely to have significant declines at late 
follow-up in patient reported function with more urgency with bowel movements (p=0.002) and more 
loose stools (p=0.009) as well as more bother with urgency (0.007) and frequency of bowel movements 
(p=0.009). There were also trends towards more bother from watery bowel movements (p=0.06) and 
incontinence (p=0.08) in men without hydrogel rectal spacer.  
 
Evaluating differences in PRO by comparing randomized data to non-randomized data did not reveal any 
differences in patient reported bowel QOL at any time points beyond 3 months of follow up and even at 
that point were not clinically relevant of MIDx1 and potentially due to baseline statistical differences in 




The results of this analysis fit within the broad reproducible data regarding rectal separation and 
improved physician reported rates of toxicity and reduced declines in PROs. Declines in overall bowel 
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mirror continued accumulation of MIDs in patient reported bowel function from 12 to 36 months of 
follow up where as MIDx2 did not appear to be substantially increased with increased follow up beyond 
12 months. This suggests that many more significant declines in bowel function occur in the middle term 
of follow up and do not recover. It is possible that continued decline in either group would be possible 
with additional follow-up, but the accumulation of MIDx1 events may suggest that continued decline 
with sufficient follow-up may ultimately increase late MIDx2 events. The natural history of these 
declines reinforce that these declines are real and not occurring in a significantly delayed fashion that 
would be limited to only patients who are long term survivors.  
 
Further follow-up is needed to assess continued QOL in these cohorts, but together this represents a 
preservation of bowel function with rectal spacer utilization in the face of continued decline in p atients 
treated with prostate-seminal vesicle only radiotherapy without a rectal spacer. The plans utilized in 
either the randomized or the non-randomized cohorts were quality radiotherapy plans by accepted 
standards, but the results of are important to place into context of the intervention.4  
 
With any intervention, there is a potential learning curve to both placement and understanding 
dosimetric feasibility. Given that this represents the first experience with rectal separation, these results 
may underrepresent differences in optimized plans with rectal spacers with adequate experience. While 
placement geometric evaluation had failed to provide hints at ideal localization of rectal separation and 
PROSQA analysis allowed for optimization of dosimetric constraints without rectal spacer, future 
dosimetric analysis within patients with rectal spacers will provide important information for 
practitioners.6  
 
Furthermore, no patients have been able to be found on subset analysis whom did not benefit from 
rectal separation with regards to rectal quality of life. Prostate volume, pre-rectal gel placement  
dosimetry, distance of rectal separation, geometry of placement, and prior pelvic and/or abdominal 
surgery did not impact QOL in previous analysis.6,7  All patients experienced such a significant decline in 
rectal dose receiving 70 Gy that all patients benefited from the placement with relative declines of >70% 
across all patients.  While there are limitations in a pooled analysis with regards to patient heterogeneity 
as well as slight differences treatment planning and follow-up regimens, it appears that no other 
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term QOL reported here with perhaps exception of brachytherapy or stereotactic radiotherapy with 
much smaller planning target margins.  
Given the timeline to clinically meaningful difference in PRO, essentially all patients treated without a 
rectal spacer will be at increased risk of these declines well wi thin their lifetime. This may provide a 
rationale for utilization of rectal spacers in patients with higher risk disease rather than the favorable 
intermediate risk cohorts evaluated here. Feasibility albeit with at some risk of microscopic spread of a 
gel insertion in cases with significant micro- or macroscopic spread beyond the prostate will have to be 
investigated in this higher risk cohort. Prospective evaluations of utilizations within high risk prostate 
cancer are also needed as this may minimize the risk of high dose region with less effect on more 
moderate dose in patients with whole pelvis radiotherapy. These results continue to reinforce that 
hydrogel rectal spacer did not merely delay inevitable declines in bowel function, but rather preserved 
patient reported quality of life.  
 
Conclusions 
Rectal hydrogel spacer effectively preserves overall patient reported bowel function in men undergoing 
radiotherapy to the prostate alone with long term follow up beyond 2 years. There were fewer declines 
in terms of both statistical decline and clinically meaningful QOL when hydrogel was utilized. Specifically, 
patients with hydrogel spacer placement had less functional decline and bother of bowel frequency and 
loose stools at late follow up.  
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(Hydroge spacerl vs 
control) 
p-value  
(Randomized vs  
Non-randomized) 
 Hydrogel  
Spacer 
Control  Hydrogel  
Spacer 
Control    




65.9 (7.8) 67.3 (6.6) 70.6 (6.5) 71.8 (7.0) 0.03 <0.0001 
Stage T2+ (%) 52  (36%) 23 (33%) 27 (27%) 16 (24%) 0.53 0.071 
Grade 7+ (%) 51 (35%) 35 (51%) 52 (53%) 35 (53%) 0.066 0.014 
% of Pos i tive Cores 
(Standard 
deviation) 
22.9 (12.7) 23.3 
(15.3) 








51.5 (19 - 
180) 
55.0 (21 - 
134) 
0.15 0.081 




93.4 (8.1) 94.5 (6.3) 94.3 (10.3) 92.9 (9.23) 0.66 0.27 




92.7 (9.4) 92.9 (7.7) 94.4 (8.6) 93.0 (8.5) 0.24 0.03 
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Table 2 EPIC Rectal Quality of Life Domain Analysis Over Time by Individual Questions with * signifying 
P > 0.05.  
 
  Control  Hydrogel  Spacer 



























7.3 16 6.2 13.6* 10.1 21.2 7.9 2.2* 
Leakage ふ≥1 
day) 
0 3.2 1.6 3.4 2 3.3 3.7 1.5 
Loose Stools 
ふ≥1 ha l fぶ 
10.1 16.7 13.2 13.6* 10.5 16.2 8.4 3.7* 
Bloody 
Stools  ふ≥1 
hal f) 
0.7 3.2 6.2 1.1 0.8 1.7 0.9* 1.5 
Pa inful  
Stools  ふ≥1 
hal f) 




13.8 32.5 20.8 18.4 7.3 24.1 11.2* 12.7 
Crampy Pain 
ふ≥1 dayぶ 













Urgency 2.9 8.9 5.4 8* 2.4 9.5 0.9* 0.8* 
Frequency 1.5 7.4 3.9 5.7* 1.2 7.9 1.4 0* 
Watery 
Bowels  
1.5 4.1 3.9 3.4 0.8 5 1.4 0 
Incontinence 0 4.9 3.9 4.6 1.2 3.4 1.4 0.8 
Bloody 
Stools  
0 1.6 3.9 1.1 0.4 0.8 1.4 0 
Pa in 0.7 0.8 3.1 1.1 1.6 4.2 0.5 0.8 















Figure 1 Mean bowel difference in EPIC bowel domain from baseline for patients with rectal spacer 
(blue) and without rectal spacer (red) overtime with the standard deviation with pairwise p-value at 



















Figure 2 Proportions of patients experiencing a minimally important clinical difference (MID, a) and 
MIDx2 (b) in overall EPIC bowel quality of life summary score with (blue) and without rectal spacer 
(red) overtime with overall numbers of evaluable patients listed at each evaluated time point.  
 
Figure 2a 
 
bju_15097_f2.docx
This	article	is	protected	by	copyright.	All	rights	reserved
A
u
th
o
r 
M
a
n
u
s
c
ri
p
t
 
Figure 1b 
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